Company intelligence / Profile preview

Acebright

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Acebright is a leading Chinese pharmaceutical group with over 12 GMP-standard manufacturing sites in China and India. The company specializes in the development and manufacture of APIs (including ARV APIs for antiretroviral therapy), oncology APIs & finished products, vitamin products, and offers integrated CDMO services from R&D to commercial scale. It is recognized as one of the top 100 pharmaceutical companies in China[1][2]. Clinical results are not directly reported; the company primarily supplies active ingredients and finished formulations for global markets.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small moleculeBiologic
Industry: Chemicals & Materials

Partnerships

Cipla/Acebright joint venture for respiratory medicines in China[5]

Beyond the preview

Go deeper on Acebright.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acebright.

Explore the full profile